Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients

Antonio Facciorusso, Valentina Del Prete, Nicola Crucinio, Nicola Muscatiello, Brian I. Carr, Alfredo Di Leo, Michele Barone

Research output: Contribution to journalArticlepeer-review


Background and Aim: Inhibition of angiotensin II synthesis seems to decrease hepatocellular carcinoma recurrence after radical therapies; however, data on the adjuvant role of angiotensin II receptor 1 blockers (sartans) are still lacking. The aim of the study was to evaluate whether sartans delay time to recurrence and prolong overall survival in hepatocellular carcinoma patients after radiofrequency ablation. Methods: Data on 153 patients were reviewed. The study population was classified into three groups: 73 (47.8%) patients who received neither angiotensin-converting enzyme inhibitors nor sartans (group 1), 49 (32%) patients treated with angiotensin-converting enzyme inhibitors (group 2), and 31 (20.2%) patients treated with sartans (group 3). Survival outcomes were analysed by means of Kaplan-Meier analysis and compared with log-rank test. Results: In the whole study population, 85.6% of patients were in Child-Pugh A class and 89.6% in Barcelona Clinic Liver Cancer A stage. Median maximum tumor diameter was 30mm (10-40) and alpha fetoprotein was 25 (1.1-2100) UI/mL. No differences in baseline characteristics among the three groups were reported. Median overall survival was 48 months (95% confidence interval: 31-58) in group 1, 72 months (49-89) in group 2, and 84 months (58-92) in group 3 (P=0.02). Median time to recurrence was 26 (15-42), 44 (33-72), and 69 (44-74) months in the three groups, respectively (P=0.02). Sartan therapy was a significant predictor of longer overall survival and delayed time to recurrence on multivariate analysis. Conclusion: Sartans significantly improved overall survival and time to recurrence after radiofrequency ablation in hepatocellular carcinoma patients.

Original languageEnglish
Pages (from-to)1643-1650
Number of pages8
JournalJournal of Gastroenterology and Hepatology
Issue number11
Publication statusPublished - Nov 1 2015


  • HCC
  • Liver cancer
  • RFA
  • Sartans
  • Survival

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology


Dive into the research topics of 'Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients'. Together they form a unique fingerprint.

Cite this